Ponesimod Regimen Slows Brain Ventricular Volume Increase in MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods to slow the increase in brain ventricular volume in patients with multiple sclerosis, as brain ventricle enlargement occurs more rapidly in MS patients compared to normal aging, leading to neurodegeneration and neurological impairment.
Innovation Solution
Administering ponesimod using a regimen effective to slow the increase in brain ventricular volume, which can be assessed through cognitive and physical deficiency evaluations and monitored via MRI, potentially in combination with other therapeutic agents like teriflunomide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard care treatments are used for multiple sclerosis, then treatment options are limited, but the rate of ventricular volume increase cannot be sufficiently slowed
Solution Approach 1:
The patent introduces ponesimod, a novel sphingosine-1-phosphate (S1P) receptor modulator with a specific dosing regimen (10mg once daily), to change the pharmacological parameters of MS treatment. This new treatment parameter effectively slows ventricular volume increase by 20-80% compared to standard care, providing an additional therapeutic option for patients with progressive MS who have insufficient response to conventional treatments.
2Reliability
If brain ventricle enlargement is allowed to progress naturally in MS patients, then disease progression follows its natural course, but neurological impairment and neurodegeneration worsen
Solution Approach 1:
The patent applies preliminary anti-action by administering ponesimod before significant neurological impairment occurs. The treatment proactively slows ventricular volume enlargement and brain atrophy in progressive MS patients, preventing or delaying the onset of severe neurological deficits. This is evidenced by the 20-80% reduction in ventricular volume increase rate compared to natural disease progression.
3Productivity
If ponesimod is administered using the specified regimen, then ventricular volume increase is slowed by 20% to 80%, but the treatment requires precise dosing and monitoring
Solution Approach 1:
The patent incorporates preliminary action through mandatory baseline assessments before initiating ponesimod treatment. Cognitive and physical baseline evaluations are performed upfront to establish reference points, enabling subsequent monitoring of treatment efficacy. This preliminary characterization simplifies ongoing management by providing clear benchmarks for assessing whether the 20-80% ventricular volume stabilization target is being achieved.
Data Source
AI summary
The disclosure relates to methods of slowing an increase in brain ventricular volume. In certain aspects, methods of slowing an increase in brain ventricular volume in a patient with multiple sclerosis are disclosed.